Molecular characterization of tumor tissues has identified key determinants associated with SCLC development and progression including loss of TP53 and RB1, MYC copy number amplification, and activation of the PI3K/AKT/mTOR pathway [20,21,22,23]. This evidence concerns the gene MYC and small cell lung carcinoma.